ResearchIn-Press PreviewDermatologyImmunology
Open Access | 10.1172/jci.insight.163495
1Sanofi, Cambridge, United States of America
2Global Discovery Pathology, Sanofi, Framingham, United States of America
3Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States of America
4Translational Science Single Cell & Functional Genomics, Sanofi, Framingham, United States of America
5In-vivo Research Center, Sanofi, Framingham, United States of America
Find articles by Han, H. in: JCI | PubMed | Google Scholar
1Sanofi, Cambridge, United States of America
2Global Discovery Pathology, Sanofi, Framingham, United States of America
3Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States of America
4Translational Science Single Cell & Functional Genomics, Sanofi, Framingham, United States of America
5In-vivo Research Center, Sanofi, Framingham, United States of America
Find articles by
Cummings, S.
in:
JCI
|
PubMed
|
Google Scholar
|
1Sanofi, Cambridge, United States of America
2Global Discovery Pathology, Sanofi, Framingham, United States of America
3Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States of America
4Translational Science Single Cell & Functional Genomics, Sanofi, Framingham, United States of America
5In-vivo Research Center, Sanofi, Framingham, United States of America
Find articles by Shade, K. in: JCI | PubMed | Google Scholar
1Sanofi, Cambridge, United States of America
2Global Discovery Pathology, Sanofi, Framingham, United States of America
3Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States of America
4Translational Science Single Cell & Functional Genomics, Sanofi, Framingham, United States of America
5In-vivo Research Center, Sanofi, Framingham, United States of America
Find articles by Johnson, J. in: JCI | PubMed | Google Scholar
1Sanofi, Cambridge, United States of America
2Global Discovery Pathology, Sanofi, Framingham, United States of America
3Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States of America
4Translational Science Single Cell & Functional Genomics, Sanofi, Framingham, United States of America
5In-vivo Research Center, Sanofi, Framingham, United States of America
Find articles by Qian, G. in: JCI | PubMed | Google Scholar
1Sanofi, Cambridge, United States of America
2Global Discovery Pathology, Sanofi, Framingham, United States of America
3Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States of America
4Translational Science Single Cell & Functional Genomics, Sanofi, Framingham, United States of America
5In-vivo Research Center, Sanofi, Framingham, United States of America
Find articles by
Gans, J.
in:
JCI
|
PubMed
|
Google Scholar
|
1Sanofi, Cambridge, United States of America
2Global Discovery Pathology, Sanofi, Framingham, United States of America
3Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States of America
4Translational Science Single Cell & Functional Genomics, Sanofi, Framingham, United States of America
5In-vivo Research Center, Sanofi, Framingham, United States of America
Find articles by
Shankara, S.
in:
JCI
|
PubMed
|
Google Scholar
|
1Sanofi, Cambridge, United States of America
2Global Discovery Pathology, Sanofi, Framingham, United States of America
3Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States of America
4Translational Science Single Cell & Functional Genomics, Sanofi, Framingham, United States of America
5In-vivo Research Center, Sanofi, Framingham, United States of America
Find articles by
Escobedo, J.
in:
JCI
|
PubMed
|
Google Scholar
|
1Sanofi, Cambridge, United States of America
2Global Discovery Pathology, Sanofi, Framingham, United States of America
3Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States of America
4Translational Science Single Cell & Functional Genomics, Sanofi, Framingham, United States of America
5In-vivo Research Center, Sanofi, Framingham, United States of America
Find articles by Zarazinski, E. in: JCI | PubMed | Google Scholar
1Sanofi, Cambridge, United States of America
2Global Discovery Pathology, Sanofi, Framingham, United States of America
3Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States of America
4Translational Science Single Cell & Functional Genomics, Sanofi, Framingham, United States of America
5In-vivo Research Center, Sanofi, Framingham, United States of America
Find articles by Bodinizzo, R. in: JCI | PubMed | Google Scholar
1Sanofi, Cambridge, United States of America
2Global Discovery Pathology, Sanofi, Framingham, United States of America
3Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States of America
4Translational Science Single Cell & Functional Genomics, Sanofi, Framingham, United States of America
5In-vivo Research Center, Sanofi, Framingham, United States of America
Find articles by
Bangari, D.
in:
JCI
|
PubMed
|
Google Scholar
|
1Sanofi, Cambridge, United States of America
2Global Discovery Pathology, Sanofi, Framingham, United States of America
3Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States of America
4Translational Science Single Cell & Functional Genomics, Sanofi, Framingham, United States of America
5In-vivo Research Center, Sanofi, Framingham, United States of America
Find articles by Bryce, P. in: JCI | PubMed | Google Scholar
1Sanofi, Cambridge, United States of America
2Global Discovery Pathology, Sanofi, Framingham, United States of America
3Immunology and Inflammation Research Therapeutic Area, Sanofi, Cambridge, United States of America
4Translational Science Single Cell & Functional Genomics, Sanofi, Framingham, United States of America
5In-vivo Research Center, Sanofi, Framingham, United States of America
Find articles by Hicks, A. in: JCI | PubMed | Google Scholar
Published January 10, 2023 - More info
Ocular surface diseases, including conjunctivitis, are recognized as a common comorbidity in atopic dermatitis (AD) and also occur at an increased frequency in AD patients treated with biologics targeting interleukin-4 receptor alpha (IL-4Rα) or IL-13. However, the inflammatory mechanisms underlying this pathology are unknown. Here, we developed a novel mouse model of skin inflammation-evoked conjunctivitis and showed that it is dependent on CD4+ T cells and basophils. Blockade of IL-4Rα partially attenuated conjunctivitis development, downregulated basophil activation and led to a reduction in expression of genes related to type 2 cytokine responses. Together, these data suggest that an IL-4Rα-basophil axis plays a role in the development of murine allergic conjunctivitis. Interestingly, we found a significant augmentation of a number of genes that encode tear proteins and enzymes in anti-IL-4Rα-treated mice, which may underlie the partial efficacy in this model and may represent candidate mediators of the increased frequency of conjunctivitis following dupilumab in AD patients.